Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel

References

• Antoni L. (2014). Intestinal barrier in inflammatory bowel disease. WJG 20:1165–79.
   PubMed Web of Science ®Google Scholar
• Bayless TM, Hanauer S. (2011). Advanced therapy of inflammatory disease: Volume 1: IBD and ulcerative colitis. Shelton, CT: People's Medical publishing house. pp. 330.
   Google Scholar
• Carmeliet P, Jain RK. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307.
   PubMed Web of Science ®Google Scholar
• Carrillo de Santa Pau E, Arias FC, Caso Peláez E, et al. (2009). Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 115:1701–12.
   PubMed Web of Science ®Google Scholar
• Chen N, Brachmann C, Liu X, et al. (2015). Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol 76:699–712.
   PubMed Web of Science ®Google Scholar
• Clarke JM, Hurwitz HI. (2013). Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 13:1187–96.
   PubMed Web of Science ®Google Scholar
• Damhofer H, Ebbing EA, Steins A, et al. (2015). Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J Transl Med 13:115.
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, et al. (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Drugs 19:899–909.
   PubMed Web of Science ®Google Scholar
• Fala L. (2015). Cyramza (Ramucirumab) approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer. Am Health Drug Benefits 8:49–53.
   PubMedGoogle Scholar
• Franco M, Man S, Chen L, et al. (2006). Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66:3639.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–9.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–73.
   PubMed Web of Science ®Google Scholar
• González-Moreno S, González-Bayón LA, Ortega-Pérez G. (2010). Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest oncol 2:68–75.
   PubMed Web of Science ®Google Scholar
• Gustafson DL, Merz AL, Long ME. (2005). Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett 220:161–9.
   PubMed Web of Science ®Google Scholar
• Hirashima Y, Yamada Y, Matsubara J, et al. (2009). Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci 100:310–15.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yuan J, Righi E, et al. (2012). Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Nat Acad Sci USA 109:17561–6.
   PubMed Web of Science ®Google Scholar
• Johansson MEV, Gustafsson JK, Holmén-Larsson J, et al. (2014). Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 63:281–91.
   PubMed Web of Science ®Google Scholar
• Kamba T. (2005). VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Heart Circulat Physiol 290:H560–76.
   PubMed Web of Science ®Google Scholar
• Kampen KR. (2012). The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anti-Cancer Drugs 23:347–54.
   PubMed Web of Science ®Google Scholar
• Kiessling F, Fink C, Hansen M, et al. (2002). Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity. Invest Radiol 37:193–8.
   PubMed Web of Science ®Google Scholar
• Kinoshita J, Fushida S, Tsukada T, et al. (2014). Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep 32:89–96.
   PubMed Web of Science ®Google Scholar
• Knauer D, Hwang L, Lowe C, et al. (2009). Albumin-binding and angiogenic domains of SPARC located at its C-terminus. Cancer Res 69:2144.
   Web of Science ®Google Scholar
• Ma J, Waxman DJ. (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670–84.
   PubMed Web of Science ®Google Scholar
• Neesse A, Frese KK, Chan DS, et al. (2014). SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63:974–83.
   PubMed Web of Science ®Google Scholar
• Padró T, Bieker R, Ruiz S, et al. (2002). Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16:1302–10.
   PubMed Web of Science ®Google Scholar
• Riesterer O. (2006). Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12:3518–24.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Diéras V, Glaspy J, et al. (2011). RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–60.
   PubMed Web of Science ®Google Scholar
• Roviello G, Pacifico C, Corona P, et al. (2017). Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis. Invest New Drugs 35:518–23.
   PubMed Web of Science ®Google Scholar
• Rydén L, Jirström K, Bendahl P-O, et al. (2005). Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23:4695–704.
   PubMed Web of Science ®Google Scholar
• Schaumburg I. (2005). Abraxis Oncology, a Division of American Pharmaceutical Partners, Inc. Abraxane®: Prescribing information.
   Google Scholar
• Sherwood LM, Parris EE, Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–6.
   PubMed Web of Science ®Google Scholar
• Soma D, Kitayama J, Konno T, et al. (2009). Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci 100:1979–85.
   PubMed Web of Science ®Google Scholar
• Turner PV, Brabb T, Pekow C, et al. (2011). Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 50:600–13.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lambrechts D, Prenen H, et al. (2011). Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol 29:1–4.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–54.
   PubMed Web of Science ®Google Scholar
• Wang K, Qu X, Wang Y, et al. (2016). The impact of ramucirumab on survival in patients with advanced solid tumors: a systematic review and meta-analysis of randomized II/III controlled trials. Clin Drug Investig 36:27–39.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang J, Zhang L, et al. (2016). Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. J Chemother 28:328–34.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–35.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Y, Cao Z, et al. (2013). Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Nat Acad Sci 110:12018–23.
   PubMed Web of Science ®Google Scholar
• Yardley DA. (2013). nab-Paclitaxel mechanisms of action and delivery. J Control Release 170:365–72.
   PubMed Web of Science ®Google Scholar
• Young K, Smyth E, Chau I. (2015). Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Ther Adv Gastroenterol 8:373–83.
   PubMed Web of Science ®Google Scholar